Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EURO SHOCK

Financiado

Cerrado

Testing the value of a novel strategic approach and its cost efficacy to improve...

Testing the value of a novel strategic approach and its cost efficacy to improve the poor outcomes in Cardiogenic Shock Heart attacks are common and can leave survivors suffering cardiogenic shock (CGS), with its extremely high risk of early death (42% versus 4% for non-CGS) and high incidence of chronic heart failure, with its associated socio-ec... ver más

31/12/2022

ULEIC

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

UNIVERSITY OF LEICESTER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 19 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-12-31

SC1-PM-10-2017: Comparing the effectiveness of exis...

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

19 Participantes

ULEIC

946.31K€ | Lider

TUBOPLAST HISPANIA

434.35K€ | Participante

KU Leuven

517.40K€ | Participante

CHALICE MEDICAL LTD

793.75K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CULPRIT-SHOCK Multivessel versus culprit lesion only percutaneous revascul... 8M€ Cerrado

EU-CERT-ICD Comparative Effectiveness Research to Assess the Use of Prim... 8M€ Cerrado

SHOCKOMICS MULTISCALE APPROACH TO THE IDENTIFICATION OF MOLECULAR BIOMA... 7M€ Cerrado

STRICT SN The first blood biomarker to accurately STratify mortali... 120K€ Cerrado

ROBINSCA New and more individualised population based screening for c... 3M€ Cerrado

RETENTION heaRt failurE paTient managEment and iNTerventIOns usiNg con... 6M€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2017-12-05
Fecha Fin: 2022-12-31

Líder del proyecto

UNIVERSITY OF LEICESTER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Heart attacks are common and can leave survivors suffering cardiogenic shock (CGS), with its extremely high risk of early death (42% versus 4% for non-CGS) and high incidence of chronic heart failure, with its associated socio-economic disease burden (ill-health, recurrent heart failure admissions, no return to full time activities, need for expensive therapeutic devices and life-long drugs). Outcomes from CGS are even worse in, females, the elderly (mortality>70%) and high risk sub-groups. The incidence of CGS in Europe alone is >50 000 patients pa. This unacceptably high mortality/morbidity rate represents a true unmet clinical need. No clear strategy exists to improve outcomes, with ad hoc therapies given too late in a spiralling, irrecoverable process. EURO SHOCK aims to improve outcomes for CGS patients. At its core is a robust phase3 randomised trial comparing a novel strategy of very early use of ECMO (Extracorporeal Membrane Oxygenation) to current standard of care. Evidence suggests very early ECMO will halt the spiral of decline and so significantly reduce 12 month death rate and need for heart failure re-admissions. Since both costs of CGS, and ECMO are high a health-economic cost efficacy analysis will be core. A cardiac magnetic resonance imaging sub-study will test novel protocols in sick patients and provide mechanistic data. We will test transfer networks for CGS patients and analyse ECG data to determine which patients benefit most from early transfer. Our multidisciplinary consortium comprises renowned physician-scientists, statisticians, health economists and technology providers, including specialised ECMO SME. EURO SHOCK will impact on heart attack survivors, healthcare providers and Europe`s medical technology sector by 1) reducing healthcare costs associated with CGS 2) provide novel cost effective framework for cardiac interventions 3) delivering innovative healthcare technologies and 4) informing guidelines for effective CGS intervention.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores